Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Effect of Extra Virgin Olive Oil on Biomarkers of Inflammation in HIV-Infected Patients: A Randomized, Crossover, Controlled Clinical Trial (CROSBI ID 219565)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Kozić Dokmanović, Sanja ; Kolovrat, Krunoslava ; Laškaj, Renata ; Jukić, Vedrana ; Vrkić, Nada ; Begovac, Josip Effect of Extra Virgin Olive Oil on Biomarkers of Inflammation in HIV-Infected Patients: A Randomized, Crossover, Controlled Clinical Trial // Medical science monitor, 21 (2015), 2406-2413. doi: 10.12659/MSM.893881

Podaci o odgovornosti

Kozić Dokmanović, Sanja ; Kolovrat, Krunoslava ; Laškaj, Renata ; Jukić, Vedrana ; Vrkić, Nada ; Begovac, Josip

engleski

Effect of Extra Virgin Olive Oil on Biomarkers of Inflammation in HIV-Infected Patients: A Randomized, Crossover, Controlled Clinical Trial

Premature atherosclerosis in HIV- infected patients is associated with chronic infection by itself and adverse effects of antiretroviral treatment (ART). Extra virgin olive oil (EVOO) has a beneficial effect on the cardiovascular system because of its anti- inflammatory properties. The objective of this study was to determine whether the consumption of EVOO improves inflammation and atherosclerosis biomarkers in HIV-infected patients receiving ART. This randomized, crossover, controlled trial included 39 HIV-positive male participants who consumed 50 mL of EVOO or refined olive oil (ROO) daily. Four participants dropped out of the study. Leukocyte count, erythrocyte sedimentation rate (ESR), high-sensitivity C- reactive protein (hsCRP), interleukin-6, fibrinogen, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, malondialdehyde, glutathione-peroxidase, superoxide dismutase, oxidized LDL and von Willebrand factor were determined before the first and after each of the 2 intervention periods. Intervention and washout periods lasted for 20 and 14 days, respectively. In participants with >90% compliance (N=30), hsCRP concentrations were lower after EVOO intervention (geometric mean [GM], 1.70 mg/L ; 95% confidence interval [CI], 1.15–2.52) compared to ROO administration (GM, 2.92 mg/L ; 95% CI, 1.95–4.37) (p=0.035). In participants using lopinavir/ritonavir, ESR and hsCRP concentrations decreased 62% and 151%, respectively, after EVOO administration. In the whole study population (N=35) we found no difference in analyzed biomarkers after EVOO administration. Our exploratory study suggests that EVOO consumption could lower hsCRP in patients on ART.

Anti-HIV Agents; Atherosclerosis; Inflammation; Olea

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

21

2015.

2406-2413

objavljeno

1234-1010

10.12659/MSM.893881

Povezanost rada

Kliničke medicinske znanosti, Farmacija

Poveznice
Indeksiranost